和黄医药将于2025年欧洲肿瘤内科学会 (ESMO) 年会公布临床数据
Core Viewpoint - The company announced that it will present updated research data on its self-developed compounds at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting in Berlin from October 17 to 21, 2025 [1] Group 1: Research Presentations - The FRUSICA-2 registration study results of fruquintinib combined with sintilimab for second-line treatment of locally advanced or metastatic renal cell carcinoma will be presented in a mini-oral session [1] - Further analysis results of fruquintinib for endometrial cancer from the FRUSICA-1 study will be showcased in a poster presentation [1] - The SACHI and SAVANNAH studies analyzing savolitinib for non-small cell lung cancer will also be presented in the poster session [1]